SC
ACAD icon

Stempoint Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Stempoint Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.4M Buy
+242,566
New +$5.8M 1.03% 32

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Stempoint Capital's ACAD Position: Q1 2026 in Review

Stempoint Capital opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 242,566 shares worth $5.4M. The stake represents 1.03% of the portfolio and ranks #32 among its holdings.

340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Stempoint Capital held 242,566 shares of Acadia Pharmaceuticals worth $5.4M as of Q1 2026.
  • Acadia Pharmaceuticals was a new Stempoint Capital position in Q1 2026.
  • Acadia Pharmaceuticals made up 1.03% of Stempoint Capital's portfolio in Q1 2026, its #32 holding.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.